Beiken Energy Group (002828.SZ) controllers Chen Pinggui and its original concerted action person Yuan Zunhu intend to collectively reduce their shareholding by not more than 3%.
Beiken Energy (002828.SZ) announced that the company has received a notification letter from Mr. Chen Pinggui, the controlling shareholder and actual controller of the company, and Mr. Yuan Zunhu, their former concerted action person, regarding the share reduction plan. The aforementioned shareholders plan to reduce their total holdings by no more than 6,029,600 shares (3% of the total share capital of the company) through centralized auction transactions and block trades within 3 months after 15 trading days from the date of this announcement.
Beiken Energy Group (002828.SZ) announced that the company has received a notification letter from Mr. Chen Pinggui, the controlling shareholder and actual controller of the company, and his former concerted action person Mr. Yuan Zunhu, regarding their planned share reduction plan. The aforementioned shareholders plan to reduce their holdings of the company's shares by a total of no more than 6.0296 million shares (3% of the total share capital of the company) through centralized bidding transactions or block trades within 3 months after 15 trading days from the disclosure date of this announcement.
Related Articles

Mingchen Health (002919.SZ) shareholder Wu Xinling plans to reduce her shareholding by no more than 3%.

BEIJING AIRPORT (00694): Stock price and trading volume fluctuate abnormally, company business operations running smoothly, management is normal and stable.

KINTOR PHARMA-B (09939): KX-826 1.0% solution achieves the main endpoint in Phase III critical clinical trial for treating male androgenetic alopecia in Chinese adult males.
Mingchen Health (002919.SZ) shareholder Wu Xinling plans to reduce her shareholding by no more than 3%.

BEIJING AIRPORT (00694): Stock price and trading volume fluctuate abnormally, company business operations running smoothly, management is normal and stable.

KINTOR PHARMA-B (09939): KX-826 1.0% solution achieves the main endpoint in Phase III critical clinical trial for treating male androgenetic alopecia in Chinese adult males.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


